Facebook
Twitter
Telegram
Report an ErrorGemini Therapeutics Balance Sheet 2011-2024 | GMTX
Annual Balance Sheet Gemini Therapeutics
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-358 M | -193 M | -86.4 M | -1.21 M | - | - | - | - | - | - | - | - | - |
Long Term Debt |
1.44 M | 1.03 M | 1.33 M | - | - | - | - | - | - | - | - | - | - |
Long Term Debt Current |
665 K | 307 K | 319 K | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | - | - | - | - | - | - | - | - |
Total Current Liabilities |
21.4 M | 22.6 M | 13.4 M | 598 K | - | - | - | - | - | - | - | - | - |
Total Liabilities |
22.9 M | 23.6 M | 14.8 M | 4.82 M | - | - | - | - | - | - | - | - | - |
Deferred Revenue |
- | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-189 M | -112 M | -65.4 M | - | - | - | - | - | - | - | - | - | - |
Total Assets |
368 M | 200 M | 92.4 M | 122 M | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
360 M | 195 M | 88 M | 1.21 M | - | - | - | - | - | - | - | - | - |
Book Value |
345 M | 177 M | 77.7 M | 117 M | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
345 M | 177 M | -64.2 M | -21.9 M | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Quarterly Balance Sheet Gemini Therapeutics
| 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
1.61 M | 1.77 M | 945 K | 1.03 M | - | - | - | - | - | - | - | 14 M | 14 M | 14 M | 14 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
17.5 M | 13 M | 10.9 M | 23.6 M | 1.46 M | 6.44 M | 12.7 M | 15.6 M | 14.7 M | 14.7 M | 18.2 M | 30.2 M | 30.2 M | 30.2 M | 30.2 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Deferred Revenue |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-165 M | -151 M | -135 M | -112 M | -210 M | -207 M | -200 M | -185 M | -167 M | -148 M | -132 M | -113 M | -113 M | -113 M | -113 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Assets |
376 M | 384 M | 244 M | 200 M | 106 M | 113 M | 124 M | 140 M | 156 M | 172 M | 189 M | 8.32 M | 8.32 M | 8.32 M | 8.32 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
371 M | 378 M | 236 M | 195 M | 55.6 M | 65.3 M | 74.5 M | 137 M | 150 M | 168 M | 185 M | 4.5 M | 4.5 M | 4.5 M | 4.5 M | 3.31 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Book Value |
359 M | 371 M | 233 M | 177 M | 105 M | 107 M | 112 M | 125 M | 141 M | 158 M | 171 M | -21.9 M | -21.9 M | -21.9 M | -21.9 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
359 M | 371 M | 233 M | 177 M | -98.5 M | -82.8 M | -73.7 M | 125 M | 141 M | 158 M | 171 M | -21.9 M | -21.9 M | -21.9 M | -21.9 M | -10.4 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency